http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Personalis%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Tachibana+Aaron/26606258.html si-local-file:///var/storage/secattach/20260604/26606258.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Personalis%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Tachibana+Aaron/26606258.html Thu, 04 Jun 2026 16:32:00 -0400 O.13117166 PSNL http://www.streetinsider.com/SEC+Filings/Form++144++++++++Personalis%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Tachibana+Aaron/26606258.html si-local-file:///var/storage/secattach/20260604/26606258.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Personalis%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Tachibana+Aaron/26606258.html Thu, 04 Jun 2026 16:32:00 -0400 O.13117166 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Press+Releases/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html <ul class="bwlistdisc"> <li> <i>NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery</i> </li> <li> <i>Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types</i> </li> </ul> <p> FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. </p><p> “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with http://www.streetinsider.com/Business+Wire/Personalis+Highlights+Early+Colorectal+Cancer+Recurrence+Detection+and+Ultrasensitive+MRD+Performance+Across+a+Broad+Set+of+Tumor+Types+at+ASCO+2026/26586370.html Tue, 02 Jun 2026 06:00:00 -0400 A.27235249 A.31293549 A.33615634 A.50216726 O.00573636 O.02564008 O.07116439 O.13117166 O.21612337 PSNL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Personalis%2C+Inc.++++++++++For%3A+May+28++Filed+by%3A+Hall+Christopher+M/26577021.html si-local-file:///var/storage/secattach/20260529/26577021.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Personalis%2C+Inc.++++++++++For%3A+May+28++Filed+by%3A+Hall+Christopher+M/26577021.html Fri, 29 May 2026 20:45:00 -0400 O.13117166 PSNL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Personalis%2C+Inc.++++++++++For%3A+May+28++Filed+by%3A+Hall+Christopher+M/26577021.html si-local-file:///var/storage/secattach/20260529/26577021.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Personalis%2C+Inc.++++++++++For%3A+May+28++Filed+by%3A+Hall+Christopher+M/26577021.html Fri, 29 May 2026 20:45:00 -0400 O.13117166 PSNL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Personalis%2C+Inc.++++++++++For%3A+May+29++Filed+by%3A+Tachibana+Aaron/26577002.html si-local-file:///var/storage/secattach/20260529/26577002.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Personalis%2C+Inc.++++++++++For%3A+May+29++Filed+by%3A+Tachibana+Aaron/26577002.html Fri, 29 May 2026 20:27:00 -0400 O.13117166 PSNL